Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Techno DrugsDHA:TECHNODRUG -2.27%37 Median PS Value is BDT0.00 as of Jul. 24, 2026. GuruFocus rates DHA:TECHNODRUG with a GF Score™ of 37/100. The stock has 10 warning signs investors should review. Among 543 Drug Manufacturers companies, Techno Drugs ranks worse than 184161.88% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Techno Drugs's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was BDT23.499. Techno Drugs's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is BDT0.00.
As of today (2026-07-24), Techno Drugs's share price is BDT47.30. Techno Drugs's Median PS Value is BDT0.00. Therefore, Techno Drugs's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Techno Drugs's Median PS Value or its related term are showing as below:
DHA:TECHNODRUG's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.86 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Techno Drugs (DHA:TECHNODRUG) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Techno Drugs's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
47.30
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Techno Drugs Median PS Value Related Terms
Techno Drugs Median PS Value Historical Data
* Premium members only.
The historical data trend for Techno Drugs's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:TECHNODRUG vs ZTS, UTHR, VTRS: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Techno Drugs's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Techno Drugs Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Techno Drugs's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Techno Drugs's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Techno Drugs's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT23.499.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Techno Drugs (DHA:TECHNODRUG) has a Median PS Value of BDT0.00 as of Jul. 24, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Techno Drugs and its competitors. According to the industry distribution chart, Techno Drugs ranks #999999 out of 543 companies in the Drug Manufacturers industry.
Is Techno Drugs' Median PS Value too high?
Techno Drugs' current Median PS Value is BDT0.00. Based on the distribution chart, Techno Drugs ranks #999999 out of 543 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Techno Drugs ranks #999999 out of 543 companies for Median PS Value. This places Techno Drugs in the lower half of its industry. The industry median Median PS Value is 0.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.86, based on 543 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Techno Drugs and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Techno Drugs's current Median PS Value is BDT0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current Median PS Value of BDT0.00. The current Median PS Value is BDT0.00. Techno Drugs' overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current Median PS Value is BDT0.00 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score
Get the complete analysis for DHA:TECHNODRUG
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:TECHNODRUG has been successfully added to your 
